Just after market close today, we issued a press release with earnings results for the fourth quarter and full-year 2025. Starting with our full-year results, our HIV business grew 6% year-over-year, driven by 7% growth in Biktarvy and 47% growth in our HIV prevention portfolio. Our liver business grew 6% in 2025 compared to 2024, largely driven by the rapid adoption of Livdelzi for primary biliary cholangitis. In oncology, Trodelvy also grew 6% in 2025, driven by momentum in metastatic triple-negative breast cancer following positive phase III updates.
The strength and the pace of progress in our clinical pipeline is driving a steady cadence of product launches. We have up to 10 ongoing and potential new launches through 2027 and the strongest pipeline in our almost 40-year history. Sequentially, HIV sales were up 10%, primarily driven by seasonal inventory dynamics and higher average realized price due to favorable channel mix in addition to demand. For the full-year, HIV sales of $20.8 billion were up 6% year-over-year, driven by strong underlying demand growth.
Our exceptional commercial performance and higher than expected average realized price exceeded our updated guidance of 5% growth. Excluding the estimated $900 million headwind associated with the Medicare Part D redesign, our HIV business grew 10% year-over-year. This demand-led growth reflects 2%-3% treatment market growth annually and continued Biktarvy share gains. Now, moving to slide 11, we've had another exceptional quarter for our HIV prevention business, which grew 53% year-over-year, driven by favorable access, strong commercial execution, and continued U.S.